10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-VEGF Reference Antibody (BioMab patent anti-VEGF)

Recombinant Antibody
Catalog # APR10217

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P15692
Reactivity	Human
Clonality	Monoclonal
Isotype	Human IgG1
Calculated MW	146 KDa

Additional Information


Target/Specificity	VEGF
Endotoxin	
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information


Images




Anti- Human VEGF(Bevacizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti- Human VEGF(Bevacizumab) is 97.8%, determined by SEC-HPLC.



Immobilized human VEGFA (His Tag, 2 μg/mL) can bind to Anti- Human VEGF(Bevacizumab) with an EC50 of 0.003018 ug/mL.



Anti- Human VEGF(Bevacizumab) inhibited the tumor growth of COLO205 on balb/c nude mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 42.0% at 0.95 mpk at D31.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.